Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

Functional characterization of the role of the tyrosine-protein kinase BAZ1B in hormone- responsive breast cancer cells


ABSTRACT: Breast Cancer (BC) is one of the main causes of cancer-related death in women. The most widespread BC subtype (75%) is the hormone-dependent, characterized by high expression of Estrogen Receptor Alpha (ERa). ERa exerts its oncogenic activity through the interaction with different co-regulators, carrying out a direct control on gene transcription and thus being the target of specific anticancer therapies. Despite the efficiency of these drugs, 30% of patients develop de novo or acquired resistance mechanisms, caused by alternative mechanisms that bypass antiestrogenic effects determining the onset of relapse. In order to identify new and potentially drugable Era molecular partners, essential genes for BC progression in luminal cell lines assessed by CRISPR-cas assay were compared to ERa interactome, dropping our focus on the tyrosine-protein kinase BAZ1B. BAZ1B is an essential component of the WICH complex and plays a crucial role in chromatin remodelling acting also as transcription regulator. In order to characterize the functional role of BAZ1B in luminal BC, we first employed a TCGA analysis that showed higher expression of BAZ1B in luminal BC associated with a worst overall survival and progression free survival of patient affected by this disease. A transcriptome profiling after BAZ1B silencing was performed in MCF-7 cells, highlighting an impact of modulated genes in key BC pathways including the estrogen signalling. BAZ1B silencing showed also an effect on cell growth, inhibiting cell proliferation and increasing apoptosis activation mechanisms promoted by the loss of ERa protein expression coupled to a reduction of the receptor transactivation activity. Interesting, these effects were confirmed also in antiestrogen (Tamoxifen and Fulvestrant) resistant BC cell models that retain ERa expression, suggesting BAZ1B as a novel and potentially exploitable therapeutic target in the treatment of both hormone dependent and resistant mammary tumours.

INSTRUMENT(S): Illumina NovaSeq 6000

ORGANISM(S): Homo sapiens

SUBMITTER: Giorgio Giurato 

PROVIDER: E-MTAB-11142 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

Similar Datasets

2015-07-01 | E-GEOD-69118 | biostudies-arrayexpress
2023-02-21 | E-MTAB-12635 | biostudies-arrayexpress
2019-02-08 | E-MTAB-6875 | biostudies-arrayexpress
2011-07-17 | E-GEOD-27444 | biostudies-arrayexpress
2012-06-25 | E-MTAB-1196 | biostudies-arrayexpress
2019-02-08 | E-MTAB-6871 | biostudies-arrayexpress
2019-11-08 | PXD006732 | Pride
2008-05-22 | E-GEOD-10466 | biostudies-arrayexpress
2012-01-01 | E-GEOD-32670 | biostudies-arrayexpress
2014-02-01 | E-GEOD-44203 | biostudies-arrayexpress